000K  utf8
1100  $c2021
1500  eng
2050  urn:nbn:de:gbv:8:3-2021-00414-4
2051  10.3389/fneur.2021.640137
3000  Elben, Saskia
3010  Becker, Sara
3010  Dimenshteyn, Karina
3010  Folkerts, Ann-Kristin
3010  Kalbe, Elke
3010  Liepelt-Scarfone, Inga
3010  Ophey, Anja
3010  Schmidt, Nele
3010  Sulzer, Patricia
3010  Tödt, Inken
3010  Trenado, Carlos
3010  Witt, Karsten
3010  Wojtecki, Lars
3010  Yilmaz, Rezzak
4000  Screen Fast, Screen Faster$dA Pilot Study to Screen for Depressive Symptoms Using the Beck Depression Inventory Fast Screen in Parkinson's Disease With Mild Cognitive Impairment  [Elben, Saskia]
4209  Objective: Depressive symptoms have a high prevalence in patients with Parkinson's disease (PD) and are associated with cognitive dysfunction. Especially in PD with mild cognitive impairment (MCI), a time-efficient and valid instrument for the assessment of depression primarily focusing on psychological symptoms and disregarding confounding somatic symptoms is needed. We performed an examination of the psychometric properties of the Beck Depression Inventory II (BDI-II) and the Beck Depression Inventory Fast Screen (BDI-FS). Methods: The sample consisted of 64 patients [22 females and 42 males, mean age: 67.27 years (SD = 7.32)]. Depressive symptoms were measured in a cohort of PD patients with MCI. For the BDI-II and BDI-FS the psychometric concepts of internal consistency, convergent validity and diagnostic agreement were assessed. Results: Patients gave higher ratings on test items addressing somatic symptoms than those addressing non-somatic ones. The correlation between the absolute total scores of the BDI-II and the BDI-FS was significant (r = 0.91, p < 0.001), which indicated convergent validity. The Cronbach's alpha values indicated adequate internal consistencies for both measures (BDI-II: 0.84; BDI-FS: 0.78). There was a higher than chance level agreement of diagnoses of the two questionnaires, measured by Cohen's kappa (0.58, p < 0.001). The agreements between previous diagnosis of depression and the diagnoses of the BDI-II/BDI-FS were also significantly higher than chance level (BDI-II: 0.34, p = 0.007, BDI-FS: 0.39, p = 0.002). Additional AUC analysis across different cutoffs showed that performance of BDI-FS was better than BDI-II, supporting the observation of an equivalent or better performance of BDI-FS than BDI-II. Importantly, AUC analysis confirmed that a cutoff = 4 for BDI-FS was suitable in the considered sample of patients with PD-MCI. Discussion: In a cohort of PD-MCI, the BDI-FS demonstrates adequate psychometric properties in comparison to the BDI-II and can be used as a screening measure for assessing depression in cognitively impaired PD patients, focusing solely on psychological symptoms. Still, further research is needed to validate this instrument.
4950  https://doi.org/10.3389/fneur.2021.640137$xR$3Volltext$534
4950  https://nbn-resolving.org/urn:nbn:de:gbv:8:3-2021-00414-4$xR$3Volltext$534
4961  https://macau.uni-kiel.de/receive/macau_mods_00001419
5051  610
5550  Bdi-Fs
5550  Bdi-ii
5550  Depression
5550  Mild Cognitive Impairment
5550  Parkinson's Disease